Literature DB >> 29678874

Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.

Alvaro Teijeira1,2, Sara Labiano3, Saray Garasa3, Iñaki Etxeberria3, Eva Santamaría3,4, Ana Rouzaut3,2, Michel Enamorado5, Arantza Azpilikueta3,2, Susana Inoges3, Elixabet Bolaños3,2, Maria Angela Aznar3, Alfonso R Sánchez-Paulete3,2, David Sancho5, Ignacio Melero1,2.   

Abstract

T and NK lymphocytes express CD137 (4-1BB), a costimulatory receptor of the TNFR family whose function is exploitable for cancer immunotherapy. Mitochondria regulate the function and survival of T lymphocytes. Herein, we show that CD137 costimulation provided by agonist mAb and CD137L (4-1BBL) induced mitochondria enlargement that resulted in enhanced mitochondrial mass and transmembrane potential in human and mouse CD8+ T cells. Such mitochondrial changes increased T-cell respiratory capacities and were critically dependent on mitochondrial fusion protein OPA-1 expression. Mass and function of mitochondria in tumor-reactive CD8+ T cells from cancer-bearing mice were invigorated by agonist mAb to CD137, whereas mitochondrial baseline mass and function were depressed in CD137-deficient tumor reactive T cells. Tumor rejection induced by the synergistic combination of adoptive T-cell therapy and agonistic anti-CD137 was critically dependent on OPA-1 expression in transferred CD8+ T cells. Moreover, stimulation of CD137 with CD137 mAb in short-term cultures of human tumor-infiltrating lymphocytes led to mitochondria enlargement and increased transmembrane potential. Collectively, these data point to a critical link between mitochondrial morphology and function and enhanced antitumor effector activity upon CD137 costimulation of T cells. Cancer Immunol Res; 6(7); 798-811. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29678874     DOI: 10.1158/2326-6066.CIR-17-0767

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  29 in total

1.  Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.

Authors:  Ugur Eskiocak; Wilson Guzman; Benjamin Wolf; Christine Cummings; Lauren Milling; Hsin-Jung Wu; Michael Ophir; Conner Lambden; Pearl Bakhru; Dana C Gilmore; Samantha Ottinger; Lucy Liu; William K McConaughy; Sunny Q He; Chao Wang; Cheuk Lun Leung; Jason Lajoie; William F Carson; Nora Zizlsperger; Michael M Schmidt; Ana C Anderson; Piotr Bobrowicz; Thomas J Schuetz; Robert Tighe
Journal:  JCI Insight       Date:  2020-03-12

2.  CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors.

Authors:  Huanpeng Chen; Fengjiao Wei; Meng Yin; Qingyu Zhao; Zhonghua Liu; Bolan Yu; Zhaofeng Huang
Journal:  Cancer Immunol Immunother       Date:  2021-01-13       Impact factor: 6.968

3.  Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy.

Authors:  Jaco A C van Bruggen; Anne W J Martens; Joseph A Fraietta; Tom Hofland; Sanne H Tonino; Eric Eldering; Mark-David Levin; Peter J Siska; Sanne Endstra; Jeffrey C Rathmell; Carl H June; David L Porter; J Joseph Melenhorst; Arnon P Kater; Gerritje J W van der Windt
Journal:  Blood       Date:  2019-05-10       Impact factor: 22.113

Review 4.  Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms.

Authors:  Iñaki Etxeberria; Irene Olivera; Elixabet Bolaños; Asunta Cirella; Álvaro Teijeira; Pedro Berraondo; Ignacio Melero
Journal:  Cell Mol Immunol       Date:  2020-05-20       Impact factor: 11.530

5.  Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.

Authors:  Camille Guillerey; Kyohei Nakamura; Andrea C Pichler; Deborah Barkauskas; Sophie Krumeich; Kimberley Stannard; Kim Miles; Heidi Harjunpää; Yuan Yu; Mika Casey; Alina I Doban; Mircea Lazar; Gunter Hartel; David Smith; Slavica Vuckovic; Michele Wl Teng; P Leif Bergsagel; Marta Chesi; Geoffrey R Hill; Ludovic Martinet; Mark J Smyth
Journal:  JCI Insight       Date:  2019-06-13

6.  Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency.

Authors:  Mohammed F Alosaimi; Manfred Hoenig; Faris Jaber; Craig D Platt; Jennifer Jones; Jacqueline Wallace; Klaus-Michael Debatin; Ansgar Schulz; Eva Jacobsen; Peter Möller; Hanan E Shamseldin; Ferdous Abdulwahab; Niema Ibrahim; Hosam Alardati; Faisal Almuhizi; Ibraheem F Abosoudah; Talal A Basha; Janet Chou; Fowzan S Alkuraya; Raif S Geha
Journal:  J Allergy Clin Immunol       Date:  2019-03-11       Impact factor: 10.793

7.  Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma.

Authors:  Yana G Najjar; Ashley V Menk; Cindy Sander; Uma Rao; Arivarasan Karunamurthy; Roma Bhatia; Shuyan Zhai; John M Kirkwood; Greg M Delgoffe
Journal:  JCI Insight       Date:  2019-03-07

8.  Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations.

Authors:  Alexandra H Mandarano; Jessica Maya; Ludovic Giloteaux; Daniel L Peterson; Marco Maynard; C Gunnar Gottschalk; Maureen R Hanson
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 9.  Metabolism of immune cells in cancer.

Authors:  Robert D Leone; Jonathan D Powell
Journal:  Nat Rev Cancer       Date:  2020-07-06       Impact factor: 60.716

Review 10.  Metabolic and epigenetic regulation of T-cell exhaustion.

Authors:  Fabien Franco; Alison Jaccard; Pedro Romero; Yi-Ru Yu; Ping-Chih Ho
Journal:  Nat Metab       Date:  2020-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.